China Development Industrial Bank (CDIB)
VC Fund
Taipei, Taiwan
China Development Industrial Bank (CDIB) is a VC fund in Taipei focused on Biotechnology and Health Care. CDIB pioneered venture capital and investment banking in Taiwan and today it remains the predominant leader in venture capital business in Taiwan with a market share of over 30%. Along with Taiwan's industrial development, CDIB has built up a wealth of experience in high-tech investment while its investment overseas has extended to the US,Japan, Korea and S.E. Asia.
- Total investments:
- 63
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries China Development Industrial Bank (CDIB) invests in
Stages China Development Industrial Bank (CDIB) invests in
Countries China Development Industrial Bank (CDIB) invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $20M–$51M
- Series C
- $7M–$54M
Investment Focus
Industry
- Biotechnology 20 (32%)
- Health Care 14 (22%)
- Pharmaceutical 10 (16%)
- Medical 9 (14%)
- Biopharma 8 (13%)
Stage
- Series B 18 (29%)
- Series C 10 (16%)
- Funding Round 10 (16%)
- Series A 9 (14%)
- Series D 7 (11%)
Country
- United States 38 (60%)
- Taiwan 7 (11%)
- China 4 (6%)
- Israel 2 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Yang Tze-kaing
President
|
President | Total investments: 0 | Find email | |
|
Meissen Chang
Equity Research Manager
|
Equity Research Manager | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Anbogen is a clinical-stage biotechnology company dedicated to developing precision anti-cancer drugs that hold the/promise of curing cancers and/or improving the lives of cancer patients worldwide. | $12.5M / Series A / Jan 31, 2024 | ||
| Elixiron Immunotherapeutics is a company developing therapeutics for cancer, neurological diseases, and inflammatory disorders. | Series A / Aug 23, 2021 | ||
| Formosa Pharmaceuticals is a biopharmaceutical firm that specializes in ophthalmology and oncology. | $21.2M / Series C / Apr 16, 2021 | ||
| Eden Biologics, formerly known as JHL Biotech ("JHL") , is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners through the provision of contract development and manufacturing services. We are specialists in manufacturing biologics, from cell line development tocommercial manufacturing with both global and regional regulatory affairs expertise. | $106M / Post-IPO Equity / May 29, 2018 | ||
| Viscovery is a leading Vision Artificial Intelligence company based on Deep Learning and Computer Vision technology. Our revolutionary visual discovery service provides image and video recognition solutions for enterprises. Established in 2013, Viscovery has collaborated with Intel, NVIDIA, AWS, and received international recognition and investmentfrom Intel, Alibaba, Quanta, CDIB, H&Q, etc.Viscovery is dedicated to providing comprehensive recognition solutions for Smart Retail, Smart E-Commerce, Smart Media, Augmented Reality, Smart Factory and more. With our R&D team based in Taipei and consisting of computer scientists and engineers with expertise in Artificial Intelligence, Computer Vision, Machine Learning and Deep Learning, Viscovery has been exploring the unlimited possibilities via Vision AI, and providing customized recognition solutions for enterprises. (www.viscovery.com) | $10M / Venture - Series Unknown / Oct 18, 2016 | ||
| Yilu Tong is an after-sales vehicle service platform. | $3M / Series A / Jul 11, 2016 | ||
| Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. They strive to enable all consumers and small businesses to have equal access to financial and other services that are inclusive, green and sustainable. | $4.5B / Series B / Apr 22, 2016 | ||
| iCHEF build the best restaurant POS in the world, and keep making it better.Believing technology should help but handicap entrepreneurship, iCHEF works with hundreds of restaurants owners to design and deliver POS technology and service that helps every restaurant to prevail in their own way. Turning enterprise level technologies intoaffordable and understandable for small restaurants, iCHEF is making opening restaurant a better business. | $5.6M / Series A / Feb 25, 2016 | ||
| Kaixindai is a peer-to-peer lending platform that provides network investment and financing services for its clients. Founded in 2012, the company is based in Nanjing, Jiangsu. | $34M / Angel / Sep 30, 2015 | ||
| WeDoctor is the world's leading medical health technology platform, created by Liao Jieyuan and his team in 2010. With the mission of “not getting medical care and being healthy and healthy”, WeDoctor is committed to using technology to empower medical care, driving the “medical insurance” ecological upgrade, and building a world-leading HMO(Health Maintenance Organization) platform to provide users with The new medical and health services of “online + offline, general + specialist” have become the health gatekeepers of hundreds of millions of families. | $394M / Private Equity / Sep 24, 2015 | ||
| See all 63 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does China Development Industrial Bank (CDIB) invest in?
China Development Industrial Bank (CDIB) invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series C stage. Most of the 63 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is China Development Industrial Bank (CDIB)'s check size?
China Development Industrial Bank (CDIB) typically joins rounds of $20M–$51M at Series B and $7M–$54M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds China Development Industrial Bank (CDIB) participates in.
How do I contact China Development Industrial Bank (CDIB)?
Public channels for China Development Industrial Bank (CDIB) include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at China Development Industrial Bank (CDIB)?
The team at China Development Industrial Bank (CDIB) includes Yang Tze-kaing (President) and Meissen Chang (Equity Research Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
